Primary CHOP Chemotherapy Followed by Involved Field Radiation Therapy in Clinical Stage I or II Aggressive Non-Hodgkin's Lymphomas.
- Author:
Chang Hee LEE
1
;
Young Hyuck IM
;
Baek Yeol RYOO
;
Seung Mo NAM
;
Mi Sook KIM
;
Yong Sik LEE
;
Kyung Kyun OH
;
Yoon Sang SHIM
;
Seong Yul YOO
;
Jhin Oh LEE
;
Tae Woong KANG
;
Yoon Koo KANG
Author Information
1. Departments of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Localized aggressive non-Hodgkins lymphoma;
CHOP chemotherapy;
Involved field radiation therapy
- MeSH:
Diagnosis;
Doxorubicin;
Drug Therapy*;
Humans;
Lymphoma, Non-Hodgkin*;
Prospective Studies;
Vincristine
- From:Journal of the Korean Cancer Association
1998;30(4):809-817
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Although radiation therapy had been the treatment of choice for localized non-Hodgkin's lymphoma(NHL), recent studies have revealed that treatment result after radiation therapy alone is not successful for localized aggressive NHL, if it is not pathologically but clinically staged. A prospective phase II trial was conducted to evaluate the therapeutic results of 4 cycles of CHOP chemotherapy followed by involved field radiation therapy in clinically staged localized aggressive NHL. MATERIALS AND METHODS: Patients with a diagnosis of aggressive NHL(all intermediate grade and immunoblastic histology in NCI working formulation), Ann Arbor stage I or II without poor prognostic factors(presence of B symptoms, bulky diseases, or 2 or more extranodal involvement) were treated with 4 cycles of CHOP(cyclophosphamide, doxorubicin, vincristine, prednisolone) followed by involved field radiation therapy of 3,000~6,000(median: 4,500) cGy. RESULTS: Between April 1990 and March 1995, 62 consecutive patients entered this trial. Forty six patients with measurable diseases were evaluable for response. Complete response was achieved in 41(89.1%) patients after CHOP chemotherapy and 4 more patients after subsequent radiation therapy, making total CR rate of 98%. Progression free survival(PFS) of all 62 patients were 2.2+~73+ months and 5 year PFS rate was 64.6%. Overall survival(OS) were 2.4+~75+ months and 5 year OS rate was 75.2%. Old age (> 60) was the only significant prognostic factor, which-affected overall survival negatively. Treatment was relatively well tolerated, but 3 patients died associated with treatment. CONCLUSIONS: Four cycles of CHOP chemotherapy followed by involved field radiation therapy is highly curative and safe treatment for clinically staged, localized aggressive NHLs.
